The Influenza Research Institute in Russia has outlined plans to begin the second phase of testing a nasal RSV vaccine designed for older adults by the end of 2023, a move tied to ongoing clinical evaluation by the national health ministry.
Officials stated that the institute has completed the first phase of clinical trials and anticipates launching the second phase at year-end. The vaccine is being developed as a nasal drop formulation intended to offer protection against respiratory syncytial virus while also delivering a bonus benefit of temporary influenza immunity for the season.
Advocates for intranasal vaccination argue that this approach targets respiratory infections at their point of entry, providing both systemic and mucosal immunity. This dual protection is seen as especially valuable for older adults, who can experience more severe outcomes from RSV and related infections.
RSV is recognized as a serious pathogen affecting vulnerable groups, including the elderly and those with underlying health conditions. Experts highlight the potential for RSV to cause severe pneumonia and bronchiolitis in seniors, underscoring the importance of effective vaccines as part of public health strategies in North America as well as globally.
World Health Organization observers have noted RSV as a priority pathogen alongside influenza and SARS-CoV-2 in its efforts to monitor and mitigate respiratory infections. The organization has emphasized tracking programs that focus on high-risk populations and supporting vaccine development and deployment where appropriate.
Readers seeking broader context on influenza vaccines and seasonal risk can consult comparative reports that summarize which vaccines are most effective for current flu seasons and how infection trends are evolving in different regions. These analyses highlight ongoing developments in vaccine science and public health responses to respiratory viruses collected from multiple health systems and research networks.
Earlier statements from public health experts highlighted that there are multiple flu vaccine types showing strong performance in the current season, reinforcing the value of informed vaccine choices for maintaining community health.